Sotac Pharmaceuticals Limited (NSE:SOTAC)

Market Cap	1.18B -17.7%
Revenue (ttm)	846.72M -19.3%
Net Income	85.60M +91.9%
EPS	7.74 +91.8%
Shares Out	11.05M
PE Ratio	13.83
Forward PE	n/a
Dividend	0.10 (0.09%)
Ex-Dividend Date	n/a

Volume	4,800
Average Volume	12,960
Open	107.50
Previous Close	107.00
Day's Range	107.50 - 112.00
52-Week Range	100.00 - 152.35
Beta	-0.12
RSI	45.16
Earnings Date	May 22, 2026

About Sotac Pharmaceuticals

Sotac Pharmaceuticals Limited engages in the production, manufacturing, processing, and sale of various pharmaceutical products in India. Its therapeutic product portfolio includes anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological solutions, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics, IP-lactams and non-IP-lactams, anti-fungal, and cephalosporin products. The compan...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2014
• Employees: 127
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SOTAC

Financial Performance

In fiscal year 2025, Sotac Pharmaceuticals's revenue was 1.00 billion, a decrease of -3.57% compared to the previous year's 1.04 billion. Earnings were 80.27 million, an increase of 87.48%.